Back to results
US 11,352,642 B2Granted
Methods and compositions for combination immunotherapy
AssigneeEtubics Corporation
InventorsFrank R. Jones, Elizabeth Gabitzsch, Yvette Latchman, Adrian Rice
Life of this patent
Estimating the term…
Abstract
Methods for generating immune responses using adenovirus vectors that allow multiple vaccinations with the same adenovirus vector and vaccinations in individuals with preexisting immunity to adenovirus are provided.
Claims14
A vaccine composition comprising:
- (a) a recombinant replication defective adenovirus 5 vector comprising an E2b gene region deletion, an E1 gene region deletion, and a nucleotide sequence encoding a MUC1-C antigen having an amino acid sequence of SEQ ID NO:9;
- (b) a recombinant replication defective adenovirus 5 vector comprising an E2b gene region deletion, an E1 gene region deletion, and a nucleotide sequence encoding a Brachyury antigen wherein the nucleotide sequence encoding the Brachyury sequence is SEQ ID NO:7 or SEQ ID NO:8;
- and
- (c) a recombinant replication defective adenovirus 5 vector comprising an E2b gene region deletion, an E1 gene region deletion, and a nucleotide sequence encoding a CEA antigen, wherein the nucleotide sequence encoding the CEA antigen is SEQ ID NO:1 or SEQ ID NO:2 and wherein an amino acid sequence of the CEA antigen comprises SEQ ID NO:10;
- and
- wherein the vaccine composition comprises at least 1×1010 virus particles (VPs) of the viral vector comprising the nucleotide sequence encoding the MUC1-C antigen, at least 1×1010 virus particles (VPs) of the viral vector comprising the nucleotide sequence encoding the Brachyury antigen, and at least 1×1010 virus particles (VPs) of the viral vector comprising the nucleotide sequence encoding the CEA antigen;
- and
- wherein (a), (b), and (c) are present in a 1:1:1 ratio of the VPs.
5 more elements
Dependencies are inferred from the claim text.